Corvus Pharmaceuticals
CRVS
47 hedge funds and large institutions have $50.2M invested in Corvus Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 7 closing their positions.
71% more call options, than puts
Call options by funds: $111K | Put options by funds: $65K
58% more capital invested
Capital invested by funds: $31.9M → $50.2M (+$18.4M)
20% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 10
7.61% more ownership
Funds ownership: 36.5% → 44.11% (+7.6%)
0% more funds holding
Funds holding: 47 → 47 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.1M |
| 2 |
SC
Samlyn Capital
New York
|
+$7.03M |
| 3 |
Millennium Management
New York
|
+$338K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$293K |
| 5 |
Morgan Stanley
New York
|
+$179K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$643K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$181K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$148K |
| 4 |
Renaissance Technologies
New York
|
-$136K |
| 5 |
Two Sigma Advisers
New York
|
-$134K |
CRVS Hedge Fund Activity: Q2 2024 in Review
47 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2024, worth a combined $50.2M — up 58% from $31.9M a quarter earlier.
Fund positioning in CRVS was balanced in Q2 2024: 7 funds opened new positions, 7 closed out, 12 added to existing stakes and 10 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $11.1M. The largest seller was BVF Inc, exiting entirely with an estimated $643K sold.
- 47 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $50.2M of Corvus Pharmaceuticals stock for Q2 2024, up 58% quarter-over-quarter.
- 7 funds opened new Corvus Pharmaceuticals positions in Q2 2024 and 7 closed out, a net change of 0 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2024 was Point72 Asset Management, an estimated $11.1M added.
- The largest Corvus Pharmaceuticals seller in Q2 2024 was BVF Inc, an estimated $643K sold.
Based on aggregated 13F filings for Q2 2024.